Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PSMB8 | P28062 | 9/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339594 | 0.78 | NOS1 (0.50) | KDM4EALDH1A1NUDT1 | |
| SCHEMBL778314 | 0.69 | HSD17B10 (1.00) | HSD17B10HTTPSMB8KDM4EGAA | |
| SCHEMBL29422383 | 0.69 | HSD17B10 (1.00) | HSD17B10HTTPSMB8KDM4EGAA | |
| SCHEMBL30834681 | 0.67 | PSMB8 (1.00) | HSD17B10HTTPSMB8KDM4EGAA | |
| SCHEMBL97140 | 0.67 | PSMB8 (1.00) | HSD17B10HTTPSMB8KDM4EGAA | |
| SCHEMBL24331221 | 0.64 | KDM4E (0.50) | HTTPSMB8KDM4EGAAALDH1A1 | |
| SCHEMBL22469868 | 0.64 | PSMB8 (0.34) | HSD17B10HTTPSMB8KDM4EGAA | |
| SCHEMBL860621 | 0.64 | PSMB8 (0.46) | HSD17B10HTTPSMB8KDM4EGAA | |
| SCHEMBL259028 | 0.64 | MAPT (0.52) | HSD17B10HTTPSMB8KDM4EALDH1A1 | |
| SCHEMBL29967265 | 0.64 | MAPT (0.52) | HSD17B10HTTPSMB8KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378791-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2022-12-01 | — | — | US | disclosed |
| US-20210069193-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2021-03-11 | — | — | US | disclosed |
| US-20190111058-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2019-04-18 | — | — | US | disclosed |
| US-9334274-B2 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334274-B2 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150246046-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2015-09-03 | — | — | US | disclosed |
| US-20140221379-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221379-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
| US-8716303-B2 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716303-B2 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2010135650-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135650-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20080124732-A1 | METHOD FOR OPTICAL MEASUREMENT OF MULTI-STRANDED NUCLEIC ACID | FUJIFILM CORPORATION | 2008-05-29 | — | — | US | disclosed |
| EP-1889880-A2 | Method for optical measurement of multi-stranded nucleic acid | FUJIFILM Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
| EP-1362894-B1 | Method for optical measurement of multi-stranded nucleic acid using cyanine dyes | FUJIFILM CORP (JP) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006051410-A1 | AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS | PFIZER INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050112770-A1 | Method for optical measurement of multi-stranded nucleic acid | FUJI PHOTO FILM CO., LTD. | 2005-05-26 | — | — | US | disclosed |
| EP-1362894-A2 | Method for optical measurement of multi-stranded nucleic acid using cyanine dyes | FUJI PHOTO FILM CO., LTD. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | HSD17B10 4129/4885HTT 2682/4885PSMB8 3098/4885 |
| US-20190111058-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | HSD17B10 3904/4885HTT 3124/4885PSMB8 2473/4885 |
| US-20220378791-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | HSD17B10 3904/4885HTT 3124/4885PSMB8 2473/4885 |
| US-20150246046-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | HSD17B10 3904/4885HTT 3124/4885PSMB8 2473/4885 |
| US-20210069193-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | HSD17B10 3904/4885HTT 3124/4885PSMB8 2473/4885 |
| US-20140221379-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | HSD17B10 4129/4885HTT 2682/4885PSMB8 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.